scholarly journals General anaesthesia of a bullous pemphigoid patient

1996 ◽  
Vol 43 (11) ◽  
pp. 1181-1181
Author(s):  
Ron Yaniv ◽  
Silviu Auslender ◽  
Henri Trau
Keyword(s):  
General Anaesthesia ◽  
Bullous Pemphigoid ◽  
Bullous Pemphigoid Patient

scholarly journals Cutaneous mucormycosis following COVID-19 Vaccination in a Bullous Pemphigoid Patient

2021 ◽  
Author(s):  
Kishan M. Shah ◽  
Cameron West ◽  
Jana Simpson ◽  
Yevgeniya B. Rainwater
Keyword(s):  
Bullous Pemphigoid ◽  
Bullous Pemphigoid Patient ◽  
Cutaneous Mucormycosis

scholarly journals Bullous hemorrhagic dermatosis due to enoxaparin use in a bullous pemphigoid patient

2017 ◽  
Vol 7 (2) ◽  
pp. 97 ◽  
Author(s):  
Ji-Su Shim ◽  
Soo Jie Chung ◽  
Byung-Keun Kim ◽  
Sae-Hoon Kim ◽  
Kyu Sang Lee ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Bullous Pemphigoid Patient

scholarly journals Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments

2017 ◽  
Vol 9 (1) ◽  
pp. 38-44 ◽  
Author(s):  
Aslı Bilgiç Temel ◽  
Cumhur Ibrahim Bassorgun ◽  
Ayşe Akman-Karakaş ◽  
Erkan Alpsoy ◽  
Soner Uzun
Keyword(s):  
Bullous Pemphigoid ◽  
Case Reports ◽  
Case Series ◽  
Efficacy And Safety ◽  
Effective Agent ◽  
Ige Binding ◽  
Specific Protocol ◽  
Humanized Monoclonal Antibody ◽  
Bullous Pemphigoid Patient ◽  
Severe Allergic Asthma

Omalizumab is a humanized monoclonal antibody which is an FDA-approved treatment of severe allergic asthma and inhibits IgE binding to FcεRI. According to increasing evidence of IgE inhibition, omalizumab was suggested as a therapeutic approach for bullous pemphigoid (BP). Rituximab has been reported to be effective in various autoimmune diseases, including autoimmune bullous dermatoses. A specific protocol for the use of rituximab to treat BP patients is not yet available. There are only small case series and case reports about the efficacy and safety of rituximab in BP. Here we present a young BP patient who responded well to rituximab therapy and was refractory to conventional and omalizumab therapies although he had elevated IgE levels and eosinophilia. Our case supports the knowledge about the effectiveness and safety of rituximab not only in pemphigus but also in BP. On the other hand, although it did not work in our case, omalizumab may be a potentially effective agent in some carefully selected patients with certain subtypes of BP.

scholarly journals A Case of Bullous Pemphigoid Patient Suggesting the Importance of Anti-BP180 Measurement

2020 ◽  
Vol 66 (5) ◽  
pp. 439-442
Author(s):  
ARUNWAN CHANTARAT ◽  
YOKO TABE ◽  
KEIICHI SASAHARA ◽  
TAKASUKE OGAWA ◽  
JEERAPA DAMRONGPOKKAPHAN ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Bullous Pemphigoid Patient

scholarly journals Severe Type of Minocycline-Induced Hyperpigmentation Mimicking Peripheral Arterial Occlusive Disease in a Bullous Pemphigoid Patient

Antibiotics ◽  
2019 ◽  
Vol 8 (3) ◽  
pp. 93 ◽  
Author(s):  
Wu ◽  
Hou ◽  
Yiang ◽  
Tsai ◽  
Lin
Keyword(s):  
Bullous Pemphigoid ◽  
Peripheral Arterial Occlusive Disease ◽  
Systemic Infection ◽  
Arterial Occlusive Disease ◽  
Occlusive Disease ◽  
Whole Body ◽  
Drug Induced ◽  
Body Tissues ◽  
Bullous Pemphigoid Patient ◽  
Peripheral Arterial

Minocycline is a tetracycline group antibiotic that is known to cause significant antibacterial and anti-inflammatory effects. Minocycline has been widely used to treat systemic infection, acne, dermatitis, and rosacea. However, various dose-related side effects of hyperpigmentation in whole body tissues have been reported. Three main types of minocycline-induced hyperpigmentation have been identified. In rare severe hyperpigmentation cases, drug-induced hyperpigmentation can mimic local cellulitis or peripheral arterial occlusive disease (PAOD). These processes require different therapeutic strategies. Therefore, early diagnosis is extremely important for physicians to determine the etiology of the hyperpigmentation, and subsequently discontinue the minocycline if indicated. We describe a rare case presenting a severe form of type III minocycline-induced hyperpigmentation mimicking peripheral arterial occlusive disease in a bullous pemphigoid patient.

Disseminated Cytomegalovirus Disease as a Cause of Prolonged Fever in a Bullous Pemphigoid Patient under Systemic Steroid Therapy

2003 ◽  
Vol 30 (4) ◽  
pp. 332-336 ◽  
Author(s):  
Daniel Sesto Casals ◽  
Eduardo de Azevedo Nunes ◽  
Celina Wakisaka Maruta ◽  
Valeria Aoki ◽  
Claudia Giuli Santi ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Steroid Therapy ◽  
Systemic Steroid ◽  
Cytomegalovirus Disease ◽  
Prolonged Fever ◽  
Systemic Steroid Therapy ◽  
Bullous Pemphigoid Patient

Childhood bullous pemphigoid associated with chronic renal allograft rejection

1998 ◽  
Vol 138 (3) ◽  
pp. 547-548 ◽  
Author(s):  
Yamazaki ◽  
Yokozeki ◽  
Katayama ◽  
Komai ◽  
Hashimoto ◽  
...  
Keyword(s):  
Bullous Pemphigoid ◽  
Allograft Rejection ◽  
Renal Allograft ◽  
Renal Allograft Rejection
Sign in / Sign up

Export Citation Format

Share Document